-
1
-
-
33847038363
-
Individualizing warfarin therapy
-
Reynolds K.K., Valdes R., Hartung B.R., Linder M.W. Individualizing warfarin therapy. Pers Med 2007, 4:11-31.
-
(2007)
Pers Med
, vol.4
, pp. 11-31
-
-
Reynolds, K.K.1
Valdes, R.2
Hartung, B.R.3
Linder, M.W.4
-
2
-
-
45949103309
-
Pharmacology and management of the vitamin K antagonists: American College of chest physicians evidence-based clinical practice guidelines (8th Edition)
-
Ansell J., Hirsh J., Hylek E., Jacobson A., Crowther M., Palareti G. Pharmacology and management of the vitamin K antagonists: American College of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008, 133:160S-198S.
-
(2008)
Chest
, vol.133
-
-
Ansell, J.1
Hirsh, J.2
Hylek, E.3
Jacobson, A.4
Crowther, M.5
Palareti, G.6
-
3
-
-
33845500310
-
Safety indicators for inpatient and outpatient oral anticoagulant care: [corrected] recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency
-
Baglin T.P., Cousins D., Keeling D.M., Perry D.J., Watson H.G. Safety indicators for inpatient and outpatient oral anticoagulant care: [corrected] recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. Br J Haematol 2007, 136:26-29.
-
(2007)
Br J Haematol
, vol.136
, pp. 26-29
-
-
Baglin, T.P.1
Cousins, D.2
Keeling, D.M.3
Perry, D.J.4
Watson, H.G.5
-
4
-
-
39449137238
-
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin
-
Flockhart D.A., O'Kane D., Williams M.S., et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008, 10:139-150.
-
(2008)
Genet Med
, vol.10
, pp. 139-150
-
-
Flockhart, D.A.1
O'Kane, D.2
Williams, M.S.3
-
5
-
-
33645466135
-
Long-term anticoagulant therapy in patients with coronary artery disease
-
Husted S.E., Ziegler B.K., Kher A. Long-term anticoagulant therapy in patients with coronary artery disease. Eur Heart J 2006, 27:913-919.
-
(2006)
Eur Heart J
, vol.27
, pp. 913-919
-
-
Husted, S.E.1
Ziegler, B.K.2
Kher, A.3
-
6
-
-
45949095568
-
Antithrombotic therapy in atrial fibrillation: American College of chest physicians evidence-based clinical practice guidelines (8th edition)
-
Singer D.E., Albers G.W., Dalen J.E., et al. Antithrombotic therapy in atrial fibrillation: American College of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:546S-592S.
-
(2008)
Chest
, vol.133
-
-
Singer, D.E.1
Albers, G.W.2
Dalen, J.E.3
-
7
-
-
57049126268
-
Dynamic pharmacogenetic models in anticoagulation therapy
-
Bon Homme M., Reynolds K.K., Valdes R., Linder M.W. Dynamic pharmacogenetic models in anticoagulation therapy. Clin Lab Med 2008, 28:539-552.
-
(2008)
Clin Lab Med
, vol.28
, pp. 539-552
-
-
Bon Homme, M.1
Reynolds, K.K.2
Valdes, R.3
Linder, M.W.4
-
8
-
-
33750106228
-
National surveillance of emergency department visits for outpatient adverse drug events
-
Budnitz D.S., Pollock D.A., Weidenbach K.N., Mendelsohn A.B., Schroeder T.J., Annest J.L. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006, 296:1858-1866.
-
(2006)
JAMA
, vol.296
, pp. 1858-1866
-
-
Budnitz, D.S.1
Pollock, D.A.2
Weidenbach, K.N.3
Mendelsohn, A.B.4
Schroeder, T.J.5
Annest, J.L.6
-
9
-
-
24944503322
-
A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity
-
Yuan H.Y., Chen J.J., Lee M.T., et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005, 14:1745-1751.
-
(2005)
Hum Mol Genet
, vol.14
, pp. 1745-1751
-
-
Yuan, H.Y.1
Chen, J.J.2
Lee, M.T.3
-
10
-
-
0033608466
-
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
-
Aithal G.P., Day C.P., Kesteven P.J., Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999, 353:717-719.
-
(1999)
Lancet
, vol.353
, pp. 717-719
-
-
Aithal, G.P.1
Day, C.P.2
Kesteven, P.J.3
Daly, A.K.4
-
11
-
-
31944446445
-
Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry
-
Reynolds M.R., Shah J., Essebag V., et al. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol 2006, 97:538-543.
-
(2006)
Am J Cardiol
, vol.97
, pp. 538-543
-
-
Reynolds, M.R.1
Shah, J.2
Essebag, V.3
-
12
-
-
10444278105
-
Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis
-
Reynolds M.W., Fahrbach K., Hauch O., et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004, 126:1938-1945.
-
(2004)
Chest
, vol.126
, pp. 1938-1945
-
-
Reynolds, M.W.1
Fahrbach, K.2
Hauch, O.3
-
13
-
-
51649084617
-
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement
-
Wang D., Chen H., Momary K.M., Cavallari L.H., Johnson J.A., Sadee W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 2008, 112:1013-1021.
-
(2008)
Blood
, vol.112
, pp. 1013-1021
-
-
Wang, D.1
Chen, H.2
Momary, K.M.3
Cavallari, L.H.4
Johnson, J.A.5
Sadee, W.6
-
14
-
-
0034872136
-
Pharmacogenetics of warfarin elimination and its clinical implications
-
Takahashi H., Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001, 40:587-603.
-
(2001)
Clin Pharmacokinet
, vol.40
, pp. 587-603
-
-
Takahashi, H.1
Echizen, H.2
-
15
-
-
0016374914
-
Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man
-
Breckenridge A., Orme M., Wesseling H., Lewis R.J., Gibbons R. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 1974, 15:424-430.
-
(1974)
Clin Pharmacol Ther
, vol.15
, pp. 424-430
-
-
Breckenridge, A.1
Orme, M.2
Wesseling, H.3
Lewis, R.J.4
Gibbons, R.5
-
16
-
-
0142103762
-
Genetic regulation of warfarin metabolism and response
-
Daly A.K., Aithal G.P. Genetic regulation of warfarin metabolism and response. Semin Vasc Med 2003, 3:231-238.
-
(2003)
Semin Vasc Med
, vol.3
, pp. 231-238
-
-
Daly, A.K.1
Aithal, G.P.2
-
17
-
-
0037565623
-
Pharmacogenetics of oral anticoagulants
-
Daly A.K., King B.P. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 2003, 13:247-252.
-
(2003)
Pharmacogenetics
, vol.13
, pp. 247-252
-
-
Daly, A.K.1
King, B.P.2
-
18
-
-
13844315559
-
CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis
-
Sanderson S., Emery J., Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005, 7:97-104.
-
(2005)
Genet Med
, vol.7
, pp. 97-104
-
-
Sanderson, S.1
Emery, J.2
Higgins, J.3
-
19
-
-
17944366735
-
Interindividual variability in sensitivity to warfarin-nature or nurture?
-
Loebstein R., Yonath H., Peleg D., et al. Interindividual variability in sensitivity to warfarin-nature or nurture?. Clin Pharmacol Ther 2001, 70:159-164.
-
(2001)
Clin Pharmacol Ther
, vol.70
, pp. 159-164
-
-
Loebstein, R.1
Yonath, H.2
Peleg, D.3
-
20
-
-
0037012465
-
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
-
Higashi M.K., Veenstra D.L., Kondo L.M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002, 287:1690-1698.
-
(2002)
JAMA
, vol.287
, pp. 1690-1698
-
-
Higashi, M.K.1
Veenstra, D.L.2
Kondo, L.M.3
-
21
-
-
0036914221
-
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
-
Scordo M.G., Pengo V., Spina E., Dahl M.L., Gusella M., Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002, 72:702-710.
-
(2002)
Clin Pharmacol Ther
, vol.72
, pp. 702-710
-
-
Scordo, M.G.1
Pengo, V.2
Spina, E.3
Dahl, M.L.4
Gusella, M.5
Padrini, R.6
-
22
-
-
0042915883
-
Warfarin dose adjustments based on CYP2C9 genetic polymorphisms
-
Linder M.W., Looney S., Adams J.E., et al. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis 2002, 14:227-232.
-
(2002)
J Thromb Thrombolysis
, vol.14
, pp. 227-232
-
-
Linder, M.W.1
Looney, S.2
Adams, J.E.3
-
23
-
-
1542346414
-
Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin
-
Kamali F., Khan T.I., King B.P., et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 2004, 75:204-212.
-
(2004)
Clin Pharmacol Ther
, vol.75
, pp. 204-212
-
-
Kamali, F.1
Khan, T.I.2
King, B.P.3
-
24
-
-
1342332251
-
Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors
-
Wadelius M., Sorlin K., Wallerman O., et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 2004, 4:40-48.
-
(2004)
Pharmacogenomics J
, vol.4
, pp. 40-48
-
-
Wadelius, M.1
Sorlin, K.2
Wallerman, O.3
-
25
-
-
1542346407
-
CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy
-
Peyvandi F., Spreafico M., Siboni S.M., Moia M., Mannucci P.M. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther 2004, 75:198-203.
-
(2004)
Clin Pharmacol Ther
, vol.75
, pp. 198-203
-
-
Peyvandi, F.1
Spreafico, M.2
Siboni, S.M.3
Moia, M.4
Mannucci, P.M.5
-
26
-
-
72949112021
-
Warfarin sensitivity genotyping: a review of the literature and summary of patient experience
-
Moyer T.P., O'Kane D.J., Baudhuin L.M., et al. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc 2009, 84:1079-1094.
-
(2009)
Mayo Clin Proc
, vol.84
, pp. 1079-1094
-
-
Moyer, T.P.1
O'Kane, D.J.2
Baudhuin, L.M.3
-
27
-
-
0029894980
-
Extremely sensitive, background-free gene detection using binary probes and beta replicase
-
Tyagi S., Landegren U., Tazi M., Lizardi P.M., Kramer F.R. Extremely sensitive, background-free gene detection using binary probes and beta replicase. Proc Natl Acad Sci USA 1996, 93:5395-5400.
-
(1996)
Proc Natl Acad Sci USA
, vol.93
, pp. 5395-5400
-
-
Tyagi, S.1
Landegren, U.2
Tazi, M.3
Lizardi, P.M.4
Kramer, F.R.5
-
28
-
-
0025500404
-
Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication
-
Guatelli J.C., Whitfield K.M., Kwoh D.Y., Barringer K.J., Richman D.D., Gingeras T.R. Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication. Proc Natl Acad Sci USA 1990, 87:7797.
-
(1990)
Proc Natl Acad Sci USA
, vol.87
, pp. 7797
-
-
Guatelli, J.C.1
Whitfield, K.M.2
Kwoh, D.Y.3
Barringer, K.J.4
Richman, D.D.5
Gingeras, T.R.6
-
29
-
-
0025214655
-
Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication
-
Guatelli J.C., Whitfield K.M., Kwoh D.Y., Barringer K.J., Richman D.D., Gingeras T.R. Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication. Proc Natl Acad Sci USA 1990, 87:1874-1878.
-
(1990)
Proc Natl Acad Sci USA
, vol.87
, pp. 1874-1878
-
-
Guatelli, J.C.1
Whitfield, K.M.2
Kwoh, D.Y.3
Barringer, K.J.4
Richman, D.D.5
Gingeras, T.R.6
-
30
-
-
0026547223
-
Isothermal in vitro amplification of DNA by a restriction enzyme/DNA polymerase system
-
Walker G.T., Little M.C., Nadeau J.G., Shank D.D. Isothermal in vitro amplification of DNA by a restriction enzyme/DNA polymerase system. Proc Natl Acad Sci USA 1992, 89:392-396.
-
(1992)
Proc Natl Acad Sci USA
, vol.89
, pp. 392-396
-
-
Walker, G.T.1
Little, M.C.2
Nadeau, J.G.3
Shank, D.D.4
-
31
-
-
0028046520
-
Terminal protein-primed DNA amplification
-
Blanco L., Lazaro J.M., de Vega M., Bonnin A., Salas M. Terminal protein-primed DNA amplification. Proc Natl Acad Sci USA 1994, 91:12198-12202.
-
(1994)
Proc Natl Acad Sci USA
, vol.91
, pp. 12198-12202
-
-
Blanco, L.1
Lazaro, J.M.2
de Vega, M.3
Bonnin, A.4
Salas, M.5
-
32
-
-
0031831323
-
Mutation detection and single-molecule counting using isothermal rolling-circle amplification
-
Lizardi P.M., Huang X., Zhu Z., Bray-Ward P., Thomas D.C., Ward D.C. Mutation detection and single-molecule counting using isothermal rolling-circle amplification. Nat Genet 1998, 19:225-232.
-
(1998)
Nat Genet
, vol.19
, pp. 225-232
-
-
Lizardi, P.M.1
Huang, X.2
Zhu, Z.3
Bray-Ward, P.4
Thomas, D.C.5
Ward, D.C.6
-
33
-
-
0032510768
-
Amplification of target-specific, ligation-dependent circular probe
-
Zhang D.Y., Brandwein M., Hsuih T.C., Li H. Amplification of target-specific, ligation-dependent circular probe. Gene 1998, 211:277-285.
-
(1998)
Gene
, vol.211
, pp. 277-285
-
-
Zhang, D.Y.1
Brandwein, M.2
Hsuih, T.C.3
Li, H.4
-
34
-
-
23844480384
-
Characterization of a thermostable UvrD helicase and its participation in helicase-dependent amplification
-
An L., Tang W., Ranalli T.A., Kim H.J., Wytiaz J., Kong H. Characterization of a thermostable UvrD helicase and its participation in helicase-dependent amplification. J Biol Chem 2005, 280:28952-28958.
-
(2005)
J Biol Chem
, vol.280
, pp. 28952-28958
-
-
An, L.1
Tang, W.2
Ranalli, T.A.3
Kim, H.J.4
Wytiaz, J.5
Kong, H.6
-
35
-
-
4444258850
-
Helicase-dependent isothermal DNA amplification
-
Vincent M., Xu Y., Kong H. Helicase-dependent isothermal DNA amplification. EMBO Rep 2004, 5:795-800.
-
(2004)
EMBO Rep
, vol.5
, pp. 795-800
-
-
Vincent, M.1
Xu, Y.2
Kong, H.3
-
36
-
-
57349156882
-
Development of isothermal TaqMan assays for detection of biothreat organisms
-
Tong Y., Tang W., Kim H.J., Pan X., Ranalli T., Kong H. Development of isothermal TaqMan assays for detection of biothreat organisms. Biotechniques 2008, 45:543-557.
-
(2008)
Biotechniques
, vol.45
, pp. 543-557
-
-
Tong, Y.1
Tang, W.2
Kim, H.J.3
Pan, X.4
Ranalli, T.5
Kong, H.6
-
37
-
-
42549147383
-
Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose
-
King C.R., Porche-Sorbet R.M., Gage B.F., et al. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am J Clin Pathol 2008, 129:876-883.
-
(2008)
Am J Clin Pathol
, vol.129
, pp. 876-883
-
-
King, C.R.1
Porche-Sorbet, R.M.2
Gage, B.F.3
-
38
-
-
33845260086
-
Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study
-
Carlquist J.F., Horne B.D., Muhlestein J.B., et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis 2006, 22:191-197.
-
(2006)
J Thromb Thrombolysis
, vol.22
, pp. 191-197
-
-
Carlquist, J.F.1
Horne, B.D.2
Muhlestein, J.B.3
-
39
-
-
34347403221
-
Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes
-
Zhu Y., Shennan M., Reynolds K.K., et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem 2007, 53:1199-1205.
-
(2007)
Clin Chem
, vol.53
, pp. 1199-1205
-
-
Zhu, Y.1
Shennan, M.2
Reynolds, K.K.3
|